Wegovy, widely popular weight loss drug, launched in India: Price, Dosage
Novo Nordisk has officially launched its anti-organism Vagovi in ​​India before the patent ending. The move aims to deal with increasing obesity rates facing competition from rival drugs.
In short
- Novo Nordisk introduced Vegovi for chronic weight management in India
- Vegovi contains semaglutide, a weekly injectable GLP -1 receptor agonist
- Wegovy comes after its rival drug Mounjaro launched in March
Danish pharmaceutical giant Novo Nordisk has officially launched its leading Motapa Drug Vagovi (Semaglutide) in India, announced Managing Director Vikrant Shrotriya on Tuesday.
The vegovi is once a weekly GLP1 receptor agonist (apart from ozmpic), which is approved in India for the treatment of old weight management in adults, which are rough or overweight with at least one weight -related health status.
Vegovi is once a weekly injection that contains semaglutide as its main component, the same compound is used in the blockbuster diabetes drug, ozmpic of Novo Nordisk.
A low-khurak version of Semaglutide has already been available in India since 2022 under the brand name Raybelus, which comes as a tablet and is used to treat type 2 diabetes.
The price of 0.25 mg, 0.5 mg, and 1 mg is priced at Rs 17,345 per month, which costs about Rs 4,366 at a weekly cost. The dose of 1.7 mg is priced at Rs 24,280 per month, while the dose of 2.4 mg, the highest, cost of Rs 26,015 for one month supply.
Semaglutide works by mimicking the action of a natural hormone in the intestine called GLP-1. This hormone sends signs to the brain that you are filled, help you to eat less and regulate blood sugar.
People using this medicine have been shown to lose about 15% of their body weight in a little more than a year (68 weeks).
Wagovi’s launch in India comes just before its patent for semaglutide next year. After that, many Indian pharmaceutical companies are expected to introduce cheap generic versions, which can make the drug more cheap for many people.
Obesity is now recognized as a major cause of serious health problems including diabetes, heart disease, kidney and liver disorders and even certain types of cancer.
Originally set for the release of 2026, Novo Nordisk started the Indian Indian Indian in response to intensive competition in 2025, especially from Eli Lily’s Maunjaro (Tirzepetide), which entered the market in March 2025.
Both Vegovi and its rival drug Mounaro (Anti-Motapa drug by Ellie Lily) are for people with Obaver 30’s body mass index (BMI).
